For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

Ernest Poku has officially joined Bayer 04 Leverkusen from Dutch side AZ.The 21-year-old winger has inked a five-year deal ...

Ernest Poku is moving to Bayer Leverkusen and has signed a contract with Erik ten Hag’s team until mid-2030. The 21-year-old ...

Bayer Leverkusen sporting director Simon Rolfes said of the club’s new acquisition: “Ernest is an excellent winger who, with ...

Nicolas Jackson has made his preferred destination clear to Chelsea. The Senegalese striker wants to leave Stamford Bridge ...

Bayer (BAYZF) on Tuesday unveiled a partnership deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

Bayer Leverkusen has signed speedy young winger Ernest Poku from AZ Alkmaar. The deal strengthens the club's Dutch connection ...

Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its pharma division’s growth prospects.

German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...